An Assessment of the Prevalence of Psoriasis in Patients with Hepatitis C
- Conditions
- chronic skin disease with increased keratinizationpsoriasis10011063
- Registration Number
- NL-OMON34745
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
1.Age 18 years or greater
2.Subjects must have a previous diagnosis of Hepatitis C. This would include all patients with a positive serology for Hepatitis C.
3.Patients in the treatment group should be treated for at least one dose, within the last 6 months, with pegylated interferon-*.
Exclusion Criteria
1.Subjects younger than 18 years old
2.Subjects with any skin disease, disease state, or physical condition that would impair evaluation of the skin, for example not able to undress or stand up.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Efficacy outcome measurement will include evaluation of the skin for either the<br /><br>presence or absence of psoriasis, through the psoriasis area severity index<br /><br>(PASI) . Additionally, patients will be evaluated for total Body Surface Area<br /><br>(BSA) involved. An average palm represents 1% of the BSA.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Not applicable</p><br>